Your essential biotech, medtech, and pharma recap — no noise, just what matters.

⚡ Executive Takeaway

We have covered individual CDMO deals throughout this series (MacroGenics/Bora $122.5M, CordenPharma/AmbioPharm, Daiichi Sankyo's $606M manufacturing charge) but have not stepped back to assess the broader CDMO landscape. The Pharma Letter's analysis does that. The outsourced manufacturing sector is booming in aggregate but the benefits are not evenly distributed. Larger CDMOs with biologics, cell therapy, and ADC capabilities are seeing strong demand and pricing power. Smaller CDMOs focused on traditional small-molecule manufacturing face commoditization, margin compression, and overcapacity in certain geographies. The Iran war supply chain disruptions, Section 232 tariffs, and BIOSECURE Act pressures are all reshaping where and how pharma manufactures, and CDMOs that positioned for these shifts early are outperforming those that did not. Merck's purchase of a WuXi Vaccines facility in Ireland is a specific data point in this dynamic: WuXi is divesting international assets as its U.S. business model faces regulatory uncertainty, and Western pharma companies are acquiring the capacity at what may prove to be favorable valuations. 👉 Read Full Analysis

🔮 What To Watch

🏭 CDMO & Manufacturing

The CDMO Boom Is Becoming More Uneven

The Pharma Letter published an analysis on June 11 examining how the outsourced manufacturing sector's growth is concentrating among fewer, larger players. Key dynamics:

Outsourced manufacturing has become part of the basic infrastructure of the pharma industry. Large drugmakers use it for flexibility, specialist capacity, and regional supply. Smaller biotechs use it because most cannot build plants of their own. But the boom is not lifting all boats equally. CDMOs with advanced capabilities (biologics, cell and gene therapy, ADC conjugation, mRNA) are seeing the strongest demand. CDMOs focused on traditional oral solid-dose manufacturing face overcapacity and pricing pressure. The Iran war, Section 232 tariffs, and BIOSECURE Act are accelerating the geographic redistribution of manufacturing capacity from Asia and the Middle East to the U.S. and Europe.

Merck Buys WuXi Vaccines Facility in Ireland MRK

Merck acquired a WuXi Vaccines manufacturing facility in Ireland, according to The Pharma Letter. The deal adds vaccine production capacity in Europe at a time when domestic and allied-nation manufacturing is increasingly valued under the Section 232 and BIOSECURE frameworks. WuXi has been divesting international assets as its U.S.-facing business model faces regulatory pressure. For Merck, the acquisition provides additional capacity for its expanding vaccine and biologics pipeline (including sac-TMT ADC manufacturing needs) in a jurisdiction outside both U.S. tariff exposure and Chinese regulatory risk.

🌍 Policy

Pharma Trade Bodies Press G7 on Innovation Agenda

Global branded drug trade bodies urged G7 leaders to put pharmaceutical innovation at the center of their economic agenda in a pre-summit statement, according to The Pharma Letter. The statement called for policies favorable to R&D investment, intellectual property protection, and regulatory harmonization. The push comes as pharma companies navigate competing policy pressures: U.S. tariffs and MFN pricing, EU healthcare reforms (Germany's Lilly/Boehringer pullback), and Chinese regulatory assertiveness (Decree No. 834).

Pfizer Weighs German Investment as Peers Push Back PFE

The Pharma Letter reported that Pfizer is weighing additional investment in Germany even as Lilly and Boehringer Ingelheim pulled more than $1B each from the country in response to a healthcare reform initiative. Pfizer's willingness to invest where competitors are withdrawing could give it a competitive positioning advantage in Europe's largest pharma market, or it could reflect a different assessment of the reform's long-term impact.

📊 Capital Markets

12 Biotechs Have IPO'd in 2026 at a Median of ~$300M

BioPharma Dive reported that a dozen drugmakers have gone public in 2026, raising a median of approximately $300M each. Total IPO proceeds exceed $3.6B. Key names: Kailera ($625M), Parabilis ($475M terms), Odyssey ($304M), Generate:Biomedicines, Seaport Therapeutics, Hemab Therapeutics. The median of $300M is approximately 3x the historical average for biotech IPOs, reflecting larger, later-stage companies entering the public market with more capital and more advanced pipelines.

🏢 Biotech Launches

Ethyreal Bio Launches with $101M for Thyroid Disease

Ethyreal Bio launched with $101M in funding on June 10 to develop an antibody therapy for thyroid disease, according to The Pharma Letter. The company targets an autoimmune-driven thyroid condition with limited current treatment options.

Orionis/Novartis Molecular Glue Collaboration

Orionis Biosciences signed a molecular glue collaboration with Novartis on June 10, according to The Pharma Letter. Molecular glues are small molecules that redirect the cell's protein degradation machinery to destroy disease-causing proteins. The modality has attracted significant pharma interest following the clinical success of cereblon modulators (BMS's mezigdomide CELMoD platform) and is viewed as a next-generation approach to targeting "undruggable" proteins.

📋 The Week in Review

📅 The Week Ahead

The CDMO landscape is bifurcating:

Winners: Large-scale biologics CDMOs (Lonza, Samsung Biologics, Fujifilm Diosynth), specialty CDMOs with ADC conjugation or cell/gene therapy capabilities, and U.S.-based CDMOs benefiting from Section 232 onshoring incentives.

Under pressure: Traditional small-molecule CDMOs facing overcapacity, Asian CDMOs facing BIOSECURE and tariff headwinds, and sub-scale players that cannot invest in the advanced capabilities pharma increasingly demands.

The MacroGenics/Bora deal ($122.5M) illustrates the dynamic: a biotech selling manufacturing assets it cannot afford to maintain to a CDMO that can. CordenPharma/AmbioPharm illustrates the consolidation play: acquiring U.S.-based peptide capacity for GLP-1 manufacturing. And Daiichi Sankyo's $606M ADC manufacturing charge illustrates the complexity: even large pharma companies struggle with advanced manufacturing at scale.

For BD teams evaluating CDMO partnerships: capability matters more than cost. The cheapest CDMO is not the best CDMO if it cannot manufacture your ADC, cell therapy, or mRNA product at commercial scale with FDA-compliant quality.

💊 WuXi: The BIOSECURE Effect

WuXi's divestiture of its Ireland vaccine facility to Merck is part of a broader pattern. WuXi AppTec, WuXi Biologics, and WuXi Vaccines have been restructuring their global operations in response to the BIOSECURE Act, which restricts U.S. government contracts with certain Chinese biotech companies. While WuXi is not directly named in the legislation, the regulatory uncertainty has prompted a strategic pivot: divest international assets, focus on the Chinese domestic market, and let Western buyers absorb the overseas capacity.

For Merck, the Ireland facility adds vaccine manufacturing in an EU jurisdiction with established regulatory frameworks and no tariff exposure to either the U.S. or China. It is a low-risk acquisition of high-value capacity.

📊 2026 IPO Scorecard

The 2026 IPO market has already doubled 2025's full-year proceeds in half the time. The median raise of $300M (approximately 3x historical average) reflects a structural shift: companies are staying private longer, raising more venture capital, and entering the public market with more advanced pipelines and larger capital needs. This benefits investors (more data before IPO) but reduces the number of IPO opportunities (fewer companies need public capital).

🎯 Catalyst Calendar: June 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →

NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →